| Aug 9 |
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
|
| Aug 9 |
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
|
| Aug 9 |
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
|
| Aug 9 |
AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell
|
| Jul 12 |
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
|
| Jul 3 |
Intuit initiated, Charter downgraded: Wall Street's top analyst calls
|
| May 21 |
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
|
